<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846118</url>
  </required_header>
  <id_info>
    <org_study_id>208-032</org_study_id>
    <nct_id>NCT00846118</nct_id>
  </id_info>
  <brief_title>Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)</brief_title>
  <official_title>Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chieko Hamada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juntendo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify whether pitavastatin prevents from cardiovascular
      events and improves the mortality in chronic hemodialysis patients with hypercholesteremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was already proved by the clinical trials that statins prevent from death and
      cardiovascular events. However, the efficacy of statins in patients with chronic hemodialysis
      has not been proved yet.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>whole observational period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction of the new onset</measure>
    <time_frame>whole observational period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>whole observational period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction of the new onset</measure>
    <time_frame>whole observational period</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>interventions for ischemic heart disease</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serious arrhythmia</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization for the heart failure</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalization for the unstable angina</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>cerebral stroke</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bone fracture</measure>
    <time_frame>whole observational period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1550</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin in addition to optimal standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>optimal standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>1-4mg/day</description>
    <arm_group_label>Pitavastatin</arm_group_label>
    <other_name>LIVALO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients under hemodialysis

          -  patients with hypercholesterolemia as defined by any of following parameters:

               -  LDL-C ≧ 100 mg / dL

               -  TC ≧ 180 mg / dL

               -  patients required cholesterol-lowering treatment by investigators.

          -  patients aged 20-75 years

          -  patients with written consent by their own volition after being provided sufficient
             explanation for the participation into this clinical trial

        Exclusion Criteria:

          -  patients taking statins or fibrates

          -  patients enrolled to the other trials using contraindication drugs of pitavastatin

          -  patients who had acute myocardial infarction within six months before the day of the
             agreement acquisition

          -  patients scheduled PCI and CABG within six months after the day of the agreement
             acquisition

          -  Patients who had diagnosis or doubt of malignant tumor

          -  patients corresponded to &quot;Contraindications&quot; of pitavastatin

          -  Familial hypercholesterolemia patients

          -  patients judged ineligible by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuhiko Tomino, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Nephrology, Juntendo University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine, Juntendo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8421</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Juntendo University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chieko Hamada</investigator_full_name>
    <investigator_title>Division of Nehprology</investigator_title>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Mortality</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

